Search results
Results from the WOW.Com Content Network
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in December 2017.
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
Ulotaront (INN Tooltip International Nonproprietary Name; [1] developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis.
Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline, a muscarinic agonist; and trospium chloride, a muscarinic antagonist. [1]
Brexpiprazole (Lu AF41156, OPC-34712; Rexulti) – atypical antipsychotic / 5-HT 1A, D 2 and D 3 receptor partial agonist and 5-HT 2A, 5-HT 2B, 5-HT 7, α 1-adrenergic, α 2-adrenergic, and H 1 receptor antagonist [10]
A large meta-analysis of 38 trials of antipsychotic drugs in schizophrenia with acute psychotic episodes showed an effect size of about 0.5. [37] There is little or no difference in efficacy among approved antipsychotic drugs, including both first- and second-generation agents. [23] [38] The efficacy of such drugs is suboptimal. Few patients ...